NIH Names John Powers III to Lead NIAID
The National Institutes of Health selected Powers, currently acting director, to head the National Institute of Allergy and Infectious Diseases.
Updated on Nov. 16, 2026 in Allergies

The National Institutes of Health selected John H. Powers III as director of the National Institute of Allergy and Infectious Diseases, announced by NIH Director Jay Bhattacharya. Powers currently serves as NIAID Acting Director and Principal Deputy Director.
Why it matters
NIAID's research agenda, recently released through a new strategic plan, will fall under Powers's oversight as the institute directs its work on infectious and allergic diseases. The institute holds an annual budget of $6.56 billion, making the leadership appointment significant for national research priorities.
Powers has authored more than 150 peer-reviewed publications and has been at NIAID since 1999, while NIAID operates on an annual budget of $6.56 billion. The announcement does not specify when his appointment takes effect or how his priorities may differ from current leadership.
The players
John H. Powers III
Powers is an infectious diseases physician and researcher who earned his medical degree from Temple University School of Medicine and has spent more than three decades in clinical, research and regulatory roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIAID is one of the 27 Institutes and Centers within the National Institutes of Health, responsible for research on infectious, immune and allergic diseases.
Jay Bhattacharya
Bhattacharya is the director of the National Institutes of Health, who announced the selection of Powers to lead NIAID.
The details
Powers serves as an infectious diseases attending physician in the NIH Clinical Center and as a professor of clinical medicine at the George Washington University School of Medicine. He received NIH Director's Awards for his work on H1N1 influenza and the COVID-19 pandemic, and co-chaired the U.S. Federal Interagency Task Force on Antimicrobial Resistance.
Timeline
1998 to 2006: Powers served at the FDA as a medical officer.
1999: Powers began service at NIAID as an infectious diseases attending physician.
November 16, 2026: NIH announced Powers's selection as NIAID director.
Health Landscape
Powers's selection follows his recognition with NIH Director's Awards for work on H1N1 influenza and the COVID-19 pandemic, linking the new leadership to the institute's recent public health responses. The appointment places a researcher with prior FDA regulatory experience at the head of an institute that funds research on infectious and allergic diseases.
For readers managing allergies, NIAID funds research into allergic disease, so leadership changes can shape which treatment and prevention studies move forward. The appointment itself does not change current clinical care or available therapies.
The takeaway
Leadership at NIAID influences which infectious and allergic disease research receives federal funding, so following institute announcements can help readers track future advances. Changes in research direction tend to appear first in strategic plans and grant priorities.
Further reading
Explore more on Allergies coverage tied to the research agenda NIAID oversees.






